Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Abedi, Mohammad Reza; Doverud, Ann-Charlotte

doi:10.3791/4414

Cited by 2 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several different techniques are available to reduce the bacterial burden in stored platelets. The 2 most common methods used for pathogen reduction are Mirasol Pathogen Reduction Technology (riboflavin + ultraviolet B light) [42] and Intercept Blood System (amotosalen + ultraviolet A light) [43]. …”

Section: Micrornas As Potential Platelet Markers Of Storage and Pathomentioning

confidence: 99%

Platelet MicroRNAs: An Overview

Dahiya

Sarachana

et al. 2015

Transfusion Medicine Reviews

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are short ~22-nucleotide noncoding RNA that have been found to influence the expression of many genes and cellular processes by either repressing translation or degrading messenger RNA transcripts. Platelet miRNA expression has been shown to be perturbed during ex vivo storage of platelets and in platelet-associated disorders. Although bioinformatics-based miRNA target predictions have been established, direct experimental validation of the role of miRNAs in platelet biology has been rather slow. Target prediction studies are, nonetheless, valuable in directing the design of appropriate experiments to test specific miRNA:messenger RNA interactions relevant to the underlying mechanisms of platelet function in general and in disease as well as in ex vivo storage-associated “storage lesions,” a collective term used to include physiologic, biochemical, and morphologic changes that occur in stored platelets. This brief review will focus on emerging human platelet miRNA studies to emphasize their potential role relevant to transfusion medicine field in terms of regulating platelet signaling pathways, markers of platelet associated disorders, and remote impactors of gene expression (intercellular biomodulators) as well as potential platelet quality markers of storage and pathogen reduction treatments.

show abstract

Section: Micrornas As Potential Platelet Markers Of Storage and Pathomentioning

confidence: 99%

Platelet MicroRNAs: An Overview

Dahiya

Sarachana

et al. 2015

Transfusion Medicine Reviews

View full text Add to dashboard Cite

show abstract

“…8 Moreover, by using the INTERCEPT Dual Storage Set for the preparation of two PR-PCs in one process, the production efficacy can be increased while costs can be reduced nearly by half. 9,10 Furthermore, INTERCEPT PR technology makes gamma irradiation obsolete, 11 as well as mandatory or optional bacterial testing.…”

Section: Introductionmentioning

confidence: 99%

Pathogen reduction of double‐dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects

2020

View full text Add to dashboard Cite

Background Pathogen reduction (PR) of platelet concentrates (PCs) contributes to the safety of platelet (PLT) transfusion by reducing the risk of transfusion‐transmitted infections and transfusion‐associated graft‐versus‐host disease. In vitro quality of pathogen‐reduced double‐dose PC (PR‐PC) made of eight whole blood (WB)‐derived buffy coats (BCs) were evaluated. Methods Eight small‐volume WB BCs from donors with at least 200 × 109 PLT/L were pooled with an additive solution to produce double‐dose PCs (DD‐PCs), which were treated with amotosalen/ultraviolet A light in a dual storage processing set, yielding 2 units of PR‐PC. Quality controls were undertaken as per European Directive for the Quality of Medicines (EDQM) guidelines. PLT recovery rates were measured. Production costs and savings were compared over the 3 years before and after PR implementation. Results In the pre‐PR period, 19 666 PCs were produced, compared to 17 307 PCs in the PR period. Single BC in the PR period had 41 ± 2 mL, hematocrit 0.39 ± 0.04 and 1.06 ± 0.18 × 1011 PLTs, and showed a recovery of 91% ± 8%. After pooling, separation, PR treatment of DD‐PC, and splitting, each single PC had 189 ± 6 mL with 2.52 ± 0.34 × 1011 PLTs, compared to 2.48 ± 0.40 in the pre‐PR period. The PLT recovery rate after PR was 87% ± 14%. EDQM requirements were met. An increase of about €12 (+7.5%) per PC from the pre‐PR to the PR period was identified. Conclusion A new production method resulting in two PR‐PCs made from pools of 8 BCs with use of one PR set was successfully introduced, and our experience of nearly 3 years demonstrated the high efficacy and in vitro quality of the PR‐PCs obtained.

show abstract

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Cited by 2 publications

References 11 publications

Platelet MicroRNAs: An Overview

Platelet MicroRNAs: An Overview

Pathogen reduction of double‐dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects

Contact Info

Product

Resources

About